Arcellx (ACLX) Share-based Compensation (2021 - 2025)
Arcellx (ACLX) recorded quarterly Share-based Compensation of $18.1 million in Q4 2025, up 0.8% quarter-over-quarter from $17.9 million in Q3 2025, and up 14.6% on a YoY basis from $15.8 million in Q4 2024.
Arcellx (ACLX) Share-based Compensation (2021 - 2025) Analysis & Trends
Arcellx's Share-based Compensation history runs 5 years deep, the most recent figure standing at $18.1 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 14.6% year-over-year to $18.1 million; the TTM figure through Dec 2025 stood at $77.9 million (up 27.51% YoY), while the FY2025 annual figure was $77.9 million, up 27.51% from the prior year.
- Share-based Compensation was $18.1 million for Q4 2025 at Arcellx, up from $17.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $23.8 million in Q1 2025 to a low of $757000.0 in Q1 2021.
- Historically, Share-based Compensation has averaged $10.5 million across 5 years, with a median of $10.5 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 491.94% in 2022, then gained 14.6% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $2.9 million in 2021, then jumped by 99.52% to $5.8 million in 2022, then soared by 83.33% to $10.6 million in 2023, then jumped by 48.55% to $15.8 million in 2024, then increased by 14.6% to $18.1 million in 2025.
- The last three Share-based Compensation figures came in at $18.1 million (Q4 2025), $17.9 million (Q3 2025), and $18.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 18.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.07 Mn |
| Dec 31, 2025 | 18.07 Mn |
| Sep 30, 2025 | 17.93 Mn |
| Sep 30, 2025 | 17.93 Mn |
| Jun 30, 2025 | 18.08 Mn |
| Jun 30, 2025 | 18.08 Mn |
| Mar 31, 2025 | 23.82 Mn |
| Mar 31, 2025 | 23.82 Mn |
| Dec 31, 2024 | 15.77 Mn |
| Dec 31, 2024 | 15.77 Mn |
| Sep 30, 2024 | 15.33 Mn |
| Sep 30, 2024 | 15.33 Mn |
| Jun 30, 2024 | 15.14 Mn |
| Jun 30, 2024 | 15.14 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Dec 31, 2023 | 10.62 Mn |
| Dec 31, 2023 | 10.62 Mn |
| Sep 30, 2023 | 10.61 Mn |
| Sep 30, 2023 | 10.61 Mn |